Peptide Research 2025: FDA Actions, Compounding Crackdowns, and Approvals
The peptide landscape has shifted dramatically in the first half of 2025. A convergence of regulatory enforcement, new drug approvals, and evolving compounding pharmacy rules has reshaped how researchers, clinicians, and biohackers access and study bioactive peptides. Whether it's the FDA's aggressive stance on GLP-1 receptor agonist compounding, new approvals expanding the therapeutic frontier, or emerging enforcement actions targeting peptide suppliers, the regulatory environment demands close attention from anyone involved in peptide science.
The GLP-1 Compounding Crackdown
The most consequential regulatory story of 2025 centers on compounded semaglutide and tirzepatide. Throughout 2024, compounding pharmacies operated under FDA shortage designations that permitted them to produce copies of these blockbuster drugs. When the FDA determined that the tirzepatide shortage had ended in October 2024, it triggered a cascade of legal and regulatory battles.
In early 2025, the FDA moved to enforce the end-of-shortage determination, issuing cease-and-desist letters to compounding pharmacies still producing tirzepatide-containing formulations. Several pharmacies challenged these actions in court, with the Outsourcing Facility Association filing suit to preserve compounding access. A federal court ruling in January 2025 temporarily blocked enforcement in some jurisdictions, but the legal landscape remains fragmented.
For semaglutide, the FDA similarly resolved the shortage designation, though Novo Nordisk's supply chain improvements lagged behind demand in certain dose strengths. The agency issued updated guidance in March 2025 clarifying that compounded versions of commercially available products violate the Federal Food, Drug, and Cosmetic Act when no valid shortage exists.
The practical impact has been significant:
New Peptide Drug Approvals
Beyond the compounding controversy, 2025 has seen meaningful progress in peptide-based therapeutics moving through the approval pipeline.
Survodutide, Boehringer Ingelheim's dual glucagon/GLP-1 receptor agonist, generated significant attention following Phase III results published in the NEJM showing up to 19% body weight reduction at 46 weeks in participants with obesity. The compound's unique glucagon receptor activity differentiates it from pure GLP-1 agonists, with Phase III SYNCHRONIZE trial data supporting a potential 2025–2026 regulatory submission.
Eli Lilly's orforglipron, an oral non-peptide GLP-1 receptor agonist, continued advancing through Phase III trials. While technically a small molecule rather than a peptide, its development was directly informed by peptide GLP-1 pharmacology. Results from the ATTAIN-1 trial demonstrated 14.7% mean weight loss at 72 weeks, potentially offering a pill-based alternative to injectable peptide therapies.
In the rare disease space, the FDA granted approval to several peptide-based therapies in late 2024 and early 2025, continuing a trend of peptides finding niches in precision medicine. The broader pipeline includes over 150 peptide therapeutics in active clinical trials according to a 2024 analysis in Nature Reviews Drug Discovery, spanning oncology, metabolic disease, and inflammatory conditions.
Enforcement Actions Against Peptide Suppliers
The FDA and Department of Justice ramped up enforcement against companies selling research peptides marketed with implicit therapeutic claims. In February 2025, the FDA issued warning letters to multiple online peptide vendors for selling unapproved new drugs, including BPC-157, PT-141, and various growth hormone secretagogues.
Key enforcement themes include:
The FDA's import alert 66-71 has been updated to include additional peptide products subject to detention without physical examination, expanding the agency's ability to intercept shipments at the border.
The Category C Controversy
One of the more nuanced regulatory developments involves the FDA's treatment of peptides under compounding "category" designations. The agency maintains lists of bulk drug substances that can be used in compounding: those nominated and under evaluation, those deemed acceptable, and those explicitly prohibited.
In 2025, the FDA added several popular research peptides to its evaluation queue, including AOD-9604 and thymosin alpha-1. The agency's Pharmacy Compounding Advisory Committee reviewed nominations for multiple peptides, with decisions potentially restricting or permitting their use in compounded formulations.
Thymosin alpha-1 presents a particularly complex case. While it is approved as Zadaxin in over 30 countries for hepatitis B and as an immune modulator, it lacks FDA approval in the United States. Research published in Annals of the New York Academy of Sciences has documented its immunomodulatory properties, but the FDA's evaluation of its suitability for compounding remains ongoing.
State-Level Regulatory Divergence
Adding complexity, several US states have enacted or proposed legislation diverging from federal FDA positions on compounded peptides. States including Texas, Florida, and Louisiana have explored legislation protecting patient access to compounded medications, including GLP-1 analogs and other peptide formulations.
This creates a patchwork regulatory environment where compounding legality may vary by jurisdiction. The Alliance for Pharmacy Compounding has been actively advocating for federal legislation clarifying compounding rights, while physician groups have raised concerns about quality control in the absence of FDA oversight.
What This Means for Research
The tightening regulatory environment has direct implications for peptide research beyond clinical settings. Academic researchers studying peptides like DSIP (delta sleep-inducing peptide), epitalon, or selank may face supply chain disruptions as enforcement actions reduce the number of suppliers.
Published research on many popular peptides remains limited to preclinical models. A 2023 systematic review noted that for BPC-157, despite hundreds of animal studies demonstrating tissue-protective effects, zero completed randomized controlled trials in humans exist in major registries.
This gap between preclinical promise and clinical evidence is precisely what regulators cite when restricting access. The research community faces a paradox: proving safety and efficacy requires clinical trials, but regulatory restrictions can limit the investigational supply needed for those trials.
Looking Ahead
Several developments expected in late 2025 could further reshape the landscape:
The interplay between innovation, patient access, and regulatory oversight remains the central tension in peptide science. As the therapeutic potential of peptides continues to expand—with applications in metabolic disease, neurodegeneration, tissue repair, and immunology—the regulatory framework governing their development and availability will shape the pace of discovery.